Ocular Therapeutix, Inc. (OCUL) vs Pharvaris N.V. (PHVS)

Ocular Therapeutix, Inc. and Pharvaris N.V. are both Biotechnology companies. Ocular Therapeutix, Inc. and Pharvaris N.V. are of similar size ($2.3B and $2.2B). Pharvaris N.V. has the higher net margin (0.00% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Pharvaris N.V. leads on 8 and Ocular Therapeutix, Inc. on 5.

Valuation

Metric OCUL PHVS Biotechnology median
P/E n/m n/m 7.88
P/S 41.70 n/m 11.47
P/B 4.17 6.23 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 31.60 n/m 10.73
Earnings yield (14.72%) (9.53%) (28.84%)
Free cash flow yield (11.75%) (8.17%) (23.03%)

Profitability

Metric OCUL PHVS Biotechnology median
Gross margin 87.11% 0.00% 65.16%
Operating margin (603.04%) 0.00% 0.00%
Net margin (579.10%) 0.00% 0.00%
Free cash flow margin (490.07%) 0.00% 0.00%
Return on equity (72.99%) (71.50%) (57.72%)
Return on assets (53.70%) (64.43%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCUL PHVS Biotechnology median
Revenue growth (TTM) (8.14%) — 5.64%
EPS growth (last fiscal year) (16.39%) (25.37%) —
Revenue growth, 5-year CAGR 24.45% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCUL PHVS Biotechnology median
Debt to equity 0.14 0.00 0.00
Current ratio 13.11 11.94 4.73
Net debt to EBITDA 2.51 1.72 0.96

Dividend

Metric OCUL PHVS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric OCUL PHVS Biotechnology median
Market cap 2.16b 2.30b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack